StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Xilio Therapeutics's total debt was $1.55M at Mar 31, 2023. For fiscal 2022 it was $3.17M, down 67.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2022Dec 31, 2022$3.17M-67.1%
FY2021Dec 31, 2021$9.63M+29.9%
FY2020Dec 31, 2020$7.41M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2023Mar 31, 2023$1.55M-80.7%
Q4 FY2022Dec 31, 2022$3.17M-67.1%
Q3 FY2022Sep 30, 2022$4.78M-50.1%
Q2 FY2022Jun 30, 2022$6.39M-13.7%
Q1 FY2022Mar 31, 2022$8.01M–
Q4 FY2021Dec 31, 2021$9.63M–
Q3 FY2021Sep 30, 2021$9.58M–
Q4 FY2020Dec 31, 2020$7.41M–

More Xilio Therapeutics figures

See a number that looks wrong?